Tag: immunooncology
OSE Immunotherapeutics presents the latest data on the BiCKI®IL-7, CLEC-1 and OSE-230 preclinical programs in Immuno-Oncology and Immuno-Inflammation At international conferences – 06/15/2023 at 07:30
Nantes, France – June 15, 2023, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that the latest scientific data has been selected for oral or poster presentations…
genOway: New commercial success of Catalog models in immuno-oncology
By Hector Chaunu Published on 08/06/2023 at 08:06 Photo credit © GenOway (Boursier.com) — genOway a French biotechnology…
OSE Immuno presents the progress of its programs in Immuno-Oncology
By Claude Leguilloux Published on 10/12/2022 at 6:34 p.m. (Boursier.com) —…
OSE Immunotherapeutics presents advances in its Immuno-Oncology programs, BiCKI®-IL-7v and CLEC-1, at international conferences – 2022-10-12 at 18:00
Nantes, France – October 12, 2022, 6 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), announces that three abstracts have been accepted for poster presentation at the 37th annual…
MaaT Pharma announces the appointment of Nathalie Corvaïa as Scientific Director and strengthens its R&D activities in immuno-oncology – 2022-10-04 at 18:12
MaaT Pharma announces today the appointment of Dr. Nathalie Corvaïa as Scientific Director. Dr. Corvaïa has over 20 years of experience leading oncology drug research and development programs and their…
Ipsen enters partnership with Marengo Therapeutics in immuno-oncology
PARIS (Agefi-Dow Jones)–Pharmaceutical groups Ipsen and Marengo Therapeutics announced on Monday that they have entered into a strategic partnership to develop two clinical-stage precision immuno-oncology treatment candidates. “This collaboration will…
Sanofi restructures its partnership with Regeneron in immuno-oncology
Sanofi restructures its partnership with Regeneron in immuno-oncology | Photo credits: (c) Sanofi Pasteur PARIS, June 2 (Reuters) – Sanofi announced on Thursday a restructuring of its collaboration with Regeneron…
OSE Immunotherapeutics will present four posters on Tedopi®, a combination of neo-epitopes in immuno-oncology, at the ASCO 2022 congress – 05/23/2022 at 18:00
Nantes, France – May 23, 2022, 6 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and its clinical partners GERCOR, ARCAGY-GINECO and the FoRT Foundation (Fondazione Ricerca Traslazionale) announce…
Presentations by OSE Immunotherapeutics at upcoming international congresses in London and Boston: ‘Immuno-Oncology Summit Europe’ and ‘Tumor Myeloid-Directed Therapies Summit’ – 05/11/2022 at 6:00 p.m.
Presentations on CLEC-1, a new myeloid checkpoint inhibitor target In cancer immunotherapy Nantes, France – May 11, 2022, 6 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) has been…
The quality of the preliminary results of the Ikoniscope20 obtained with the UConn School of Medicine in the detection of rare cells emerges above the reference standards in immuno-oncology – 02/16/2022 at 18:40
To receive all of Ikonisys’ financial information in real time, send a request by email to [email protected]. Your registration will be immediate. • The Ikoniscope20 performs immune monitoring functions in…
MaaT Pharma: Important clinical milestones are expected for 2022 in hemato-oncology and immuno-oncology
Through Hector Chaunu Published on 01/17/2022 at 6:22 p.m. Photo credit © Reuters (Boursier.com) — MaaT Pharma, a French late-stage biotechnology company, a pioneer in the development of drugs aimed…